A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

Clinical trial NCT00217594 · COMPLETED

Trial details

NCT number: NCT00217594
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndromes

Start date: 2005-07-21
Primary completion: 2017-02-06
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.